Global Fibrocystic Breast Disease Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Global Fibrocystic Breast Disease Treatment Market Segmentation, By Treatment (Medication, Fine-Needle Aspiration, Surgical Excision, Hormonal Therapy, Oral Contraceptives, and Others), Diagnosis (Breast Biopsy, Ultrasound, Mammogram, Clinical Breast Exam, and Others), Symptoms (Swelling, Pain, Tenderness, Thickening of Tissue Lumps in One or Both Breasts, and Others), Dosage (Injection, Tablets, and Others), Route of Administration (Oral, Parenteral, and Others), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)- Industry Trends and Forecast to 2033

Fibrocystic Breast Disease Treatment Market Overview

The global Fibrocystic Breast Disease Treatment market was valued at USD 6.53 billion in 2025 and is projected to reach USD 9.35 billion by 2033, growing at a CAGR of 4.60% from 2026 to 2033. The market is experiencing consistent growth driven by rising demand for safe and realistic driver training solutions, rapid advancements in simulation hardware and software, and expanding applications across automotive R&D, defense, and professional motorsport.

The increasing incidence of road accidents globally, combined with stricter government regulations on driver training and road safety, is compelling transportation authorities, driving schools, and military organizations to adopt advanced simulation technologies. Fixed-base and VR/AR-enabled simulators are replacing traditional on-road training in many markets, offering cost-effective, repeatable, and risk-free environments for skill development and autonomous vehicle validation.

Key Market Trends & Insights

• North America dominated the global Fibrocystic Breast Disease Treatment market with the largest revenue share of 36.18% in 2025, supported by advanced women’s healthcare infrastructure, rising awareness regarding early breast disease diagnosis, and increasing adoption of hormonal and minimally invasive treatment approaches.
• The Medication segment led the market with a 39.84% share in 2025, driven by widespread use of pain management therapies, hormonal medications, and supportive treatment solutions for symptom control and long-term disease management.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 7.4% from 2026 to 2033, fueled by improving healthcare accessibility, growing awareness regarding breast health, and expanding diagnostic capabilities across China, India, and Japan.
• The Hormonal Therapy segment is the fastest-growing treatment type, projected to register a CAGR of 7.1%, reflecting increasing adoption of targeted hormone-regulating therapies for managing chronic breast pain, swelling, and tissue abnormalities.
• The Hospital segment dominates the end-user category with a 44.92% revenue share in 2025, led by increasing patient visits for breast imaging, biopsy procedures, and specialized women’s healthcare services.
• Oral administration accounts for 57.26% of the market, preferred due to ease of administration, strong patient compliance, and widespread use of oral hormonal medications and pain management therapies.
• The oral segment dominated the market with a share of 61.26% in 2025 due to its high convenience, ease of administration, and strong patient preference for oral therapeutic options

Market Size & Forecast

• Global Market Value (2025): USD 6.53 Billion
• Expected Market Value (2033): USD 9.35 Billion
• Forecast CAGR (2026–2033): 4.60%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia-Pacific

Report Scope and Global Fibrocystic Breast Disease Treatment Market Segmentation

Global Fibrocystic Breast Disease Treatment Market Trends

Trend: Rising Adoption of Hormonal and Minimally Invasive Breast Care Therapies

Healthcare providers are increasingly adopting hormonal therapies, minimally invasive diagnostic procedures, and personalized breast care approaches for the treatment of fibrocystic breast disease. Advanced imaging technologies such as digital mammography, breast ultrasound, and MRI are improving early detection and differentiation between benign and malignant breast abnormalities. Hospitals and specialty women’s healthcare centers are also leveraging minimally invasive fine-needle aspiration and targeted hormonal treatment strategies to reduce breast pain, swelling, and tissue thickening while improving patient comfort and long-term disease management. In addition, growing awareness regarding preventive breast healthcare and increasing participation in routine breast screening programs are accelerating adoption of precision-based treatment approaches across developed healthcare markets.

Global Fibrocystic Breast Disease Treatment Market Dynamics

Key Market Driver: Rising Prevalence of Benign Breast Disorders and Increasing Awareness Regarding Early Breast Health Management

The increasing prevalence of benign breast disorders and hormone-related breast abnormalities is creating substantial demand for advanced fibrocystic breast disease treatment solutions globally. According to healthcare studies, fibrocystic breast changes affect nearly 50% to 60% of women at some stage of their reproductive years, significantly increasing demand for diagnostic imaging, pain management therapies, and hormonal treatment options. Pharmaceutical companies and healthcare providers are increasingly investing in hormonal therapies, non-invasive diagnostic technologies, and women’s healthcare programs to improve patient outcomes and reduce unnecessary surgical interventions. In addition, growing awareness regarding early breast examination and increasing adoption of mammography and ultrasound imaging are accelerating treatment accessibility across hospitals and specialty clinics globally.

Key Restraint/Challenge: High Diagnostic Costs and Limited Awareness in Developing Regions

A significant restraint in the global Fibrocystic Breast Disease Treatment market is the high cost associated with advanced diagnostic imaging, repeated clinical evaluations, and long-term hormonal therapy management. Modern breast imaging technologies including mammography, MRI, and biopsy procedures often require specialist supervision and continuous follow-up examinations, increasing overall healthcare expenditure for patients and healthcare systems. For instance, diagnostic breast MRI procedures in developed healthcare markets can cost several hundred to thousands of dollars depending on healthcare coverage and imaging complexity. In many low- and middle-income countries, limited awareness regarding benign breast disorders, delayed diagnosis, and inadequate access to women’s healthcare specialists continue to restrict treatment adoption. The growing burden of healthcare inequality and limited screening infrastructure in emerging healthcare systems further challenge broader market penetration globally.

Key Market Opportunity: Expansion of AI-Based Breast Imaging and Personalized Women’s Healthcare Solutions

The growing focus on AI-assisted breast imaging and personalized women’s healthcare management presents a significant market opportunity for the Fibrocystic Breast Disease Treatment market. Advances in artificial intelligence, biomarker-based diagnostics, and digital breast imaging technologies are supporting the development of more accurate and individualized treatment strategies. For instance, increasing adoption of AI-enabled mammography systems across the U.S., Germany, and Japan is improving early detection rates and reducing diagnostic errors in breast abnormality assessment. In addition, collaborations between pharmaceutical companies, diagnostic imaging providers, and women’s healthcare organizations are accelerating innovation in breast disease management solutions. Expanding healthcare infrastructure, rising investments in preventive women’s healthcare programs, and improving access to advanced diagnostic services across Asia-Pacific and Latin America are also creating substantial growth opportunities for treatment providers and pharmaceutical manufacturers globally.

Global Fibrocystic Breast Disease Treatment Market Scope

The Fibrocystic Breast Disease Treatment market is segmented on the basis of treatment, diagnosis, symptoms, dosage, route of administration, end-users, and distribution channel.

By Treatment

On the basis of treatment, the global Fibrocystic Breast Disease Treatment market is segmented into medication, fine-needle aspiration, surgical excision, hormonal therapy, oral contraceptives, and others. The medication segment dominated the market with a share of 39.84% in 2025 due to its widespread use as the first-line treatment option for pain management, inflammation reduction, and hormonal symptom control associated with fibrocystic breast disease. High adoption of non-steroidal anti-inflammatory drugs (NSAIDs), vitamin supplements, and supportive pharmacological therapies across hospitals and specialty clinics is supporting segment growth. In addition, increasing patient preference for non-invasive treatment approaches, growing awareness regarding early breast health management, and rising healthcare consultations for benign breast disorders are further reinforcing the dominance of the medication segment globally.

The hormonal therapy segment is expected to witness the fastest CAGR of 7.1% from 2026 to 2033, driven by increasing adoption of hormone-regulating therapies for severe cyclic breast pain and recurrent cystic conditions. Rising use of selective estrogen modulators, progesterone-based therapies, and targeted endocrine treatment approaches is significantly improving long-term symptom management and reducing recurrence rates among patients. Increasing prevalence of hormone-related breast disorders and growing awareness regarding advanced women’s healthcare solutions are accelerating the demand for hormonal therapies globally. Healthcare providers are increasingly recommending personalized hormonal treatment strategies to improve patient outcomes and reduce the need for invasive procedures. In addition, advancements in hormone-based drug formulations and improved safety profiles are encouraging wider clinical adoption across hospitals and specialty breast care centers. Growing investments in women’s health research and rising availability of prescription hormonal medications across developed healthcare systems are further supporting market growth. The increasing integration of diagnostic imaging with hormonal treatment planning is also enhancing treatment precision and patient monitoring capabilities. Expanding healthcare access in emerging economies, coupled with rising awareness regarding breast health screening and early treatment intervention, is further contributing to segment expansion. Moreover, increasing collaborations between pharmaceutical companies and women’s healthcare providers for advanced hormone therapy development are expected to strengthen the long-term growth outlook of the segment globally.

By Diagnosis

On the basis of diagnosis, the global Fibrocystic Breast Disease Treatment market is segmented into breast biopsy, ultrasound, mammogram, clinical breast exam, and others. The ultrasound segment dominated the market with a share of 34.92% in 2025 due to its widespread clinical use for accurate differentiation between fluid-filled cysts and solid breast masses. Ultrasound imaging provides a non-invasive, cost-effective, and highly accessible diagnostic solution, particularly among women with dense breast tissue. Increasing adoption of advanced imaging technologies, rising breast screening awareness programs, and growing preference for early diagnosis of benign breast abnormalities are supporting the segment’s dominance globally.

The breast biopsy segment is expected to witness the fastest CAGR of 6.9% from 2026 to 2033, driven by increasing demand for confirmatory diagnostic procedures in patients with suspicious breast abnormalities. Growing utilization of minimally invasive biopsy technologies, image-guided procedures, and pathology-based diagnostic assessments is improving diagnostic precision and patient management outcomes. Increasing prevalence of breast-related disorders and rising awareness regarding early differentiation between benign and malignant breast conditions are supporting segment growth globally. Healthcare providers are increasingly adopting advanced biopsy techniques to improve accuracy, reduce procedural complications, and support personalized treatment planning. In addition, technological advancements in vacuum-assisted and fine-needle biopsy procedures are reducing patient discomfort and improving clinical efficiency. Expanding investments in diagnostic imaging infrastructure and rising adoption of integrated breast care programs across hospitals and specialty clinics are further accelerating market demand. The growing focus on preventive healthcare and routine breast examination programs among women is also increasing the number of diagnostic procedures performed annually. Furthermore, increasing healthcare expenditure, favorable reimbursement policies in developed economies, and rising availability of specialized pathology services are expected to strengthen the growth potential of the breast biopsy segment over the forecast period.

By Symptoms

On the basis of symptoms, the global Fibrocystic Breast Disease Treatment market is segmented into swelling, pain, tenderness, thickening of tissue lumps in one or both breasts, and others. The pain segment dominated the market with a share of 36.41% in 2025 due to the high prevalence of cyclic breast pain among women diagnosed with fibrocystic breast disease. Increasing patient consultations for breast discomfort, hormonal fluctuations, and recurring tenderness are contributing significantly to treatment demand. In addition, growing awareness regarding early symptom monitoring and rising adoption of supportive pharmacological therapies are further strengthening the segment’s leading position in the market.

The thickening of tissue lumps in one or both breasts segment is expected to witness the fastest CAGR of 6.8% from 2026 to 2033, driven by increasing clinical attention toward early evaluation of abnormal breast tissue changes and lump detection. Rising utilization of imaging diagnostics, preventive breast screening programs, and physician recommendations for regular monitoring are supporting segment growth. Increasing awareness regarding differentiation between benign and malignant breast conditions is encouraging more women to seek early medical consultation and diagnostic testing. Healthcare providers are increasingly emphasizing routine breast examinations and imaging-based assessments to improve early identification of suspicious tissue changes. In addition, advancements in mammography, ultrasound imaging, and biopsy technologies are improving diagnostic accuracy and supporting faster clinical intervention. Growing public health campaigns related to breast cancer awareness and preventive women’s healthcare are also contributing to increasing diagnostic volumes globally. The rising prevalence of hormonal imbalances, lifestyle-related health issues, and delayed menopause among women is further increasing the incidence of fibrocystic breast symptoms. Furthermore, expanding healthcare infrastructure and improving access to specialized breast care services across emerging economies are expected to accelerate long-term segment growth globally.

By Dosage

On the basis of dosage, the global Fibrocystic Breast Disease Treatment market is segmented into injection, tablets, and others. The tablets segment dominated the market with a share of 57.48% in 2025 due to the widespread use of oral medications, hormonal therapies, pain relievers, and vitamin supplements for long-term symptom management. Tablets provide convenient administration, improved patient compliance, and cost-effective treatment accessibility across outpatient and homecare settings. In addition, increasing prescription rates for oral therapeutic agents and rising preference for non-invasive treatment options are reinforcing segment dominance globally.

The injection segment is expected to witness the fastest CAGR of 6.7% from 2026 to 2033, driven by growing adoption of injectable hormonal therapies and advanced pain management solutions for severe fibrocystic breast disease symptoms. Increasing availability of targeted biologic therapies and specialist-administered injectable treatments in hospital settings is accelerating segment growth. Healthcare providers are increasingly utilizing injectable therapies for patients requiring rapid symptom relief and improved hormonal regulation. In addition, advancements in injectable drug delivery technologies and improved formulation stability are enhancing treatment effectiveness and patient safety. Rising investments in specialty women’s healthcare services and increasing adoption of hospital-administered therapies are further contributing to market expansion. The growing prevalence of chronic hormonal disorders and severe breast pain conditions is also increasing demand for advanced injectable treatment options globally. Furthermore, expanding healthcare infrastructure, rising specialist consultations, and increasing availability of biologic therapies across developed and emerging economies are expected to strengthen the long-term growth outlook of the injection segment.

By Route of Administration

On the basis of route of administration, the global Fibrocystic Breast Disease Treatment market is segmented into oral, parenteral, and others. The oral segment dominated the market with a share of 61.26% in 2025 due to its high convenience, ease of administration, and strong patient preference for oral therapeutic options. Oral medications including pain management drugs, hormonal therapies, and nutritional supplements are widely prescribed across hospitals, clinics, and outpatient settings for long-term disease management. In addition, increasing accessibility of prescription medications and growing awareness regarding women’s breast health are further supporting segment growth.

The parenteral segment is expected to witness the fastest CAGR of 6.6% from 2026 to 2033, driven by increasing use of injectable hormonal therapies and specialist-administered treatments for severe or recurrent breast symptoms. Advancements in injectable formulations, rising hospital-based treatment procedures, and improving specialty healthcare infrastructure are contributing to the growing adoption of parenteral administration methods globally. Increasing patient demand for rapid therapeutic response and improved symptom management is accelerating the use of parenteral therapies in clinical settings. In addition, growing investments in biologic drug development and advanced injectable treatment solutions are further supporting segment growth. Healthcare providers are increasingly adopting personalized treatment approaches involving injectable therapies to improve patient outcomes and reduce recurrence risks. Rising prevalence of chronic breast-related hormonal conditions and increasing awareness regarding advanced treatment availability are also strengthening the market potential of the parenteral segment globally.

By End-Users

On the basis of end-users, the global Fibrocystic Breast Disease Treatment market is segmented into clinic, hospital, and others. The hospital segment dominated the market with a share of 44.37% in 2025 due to the availability of advanced diagnostic imaging systems, specialized breast care units, and multidisciplinary treatment services. Hospitals remain the primary healthcare setting for breast biopsies, imaging procedures, surgical interventions, and specialist consultations related to fibrocystic breast disease management. In addition, increasing patient preference for comprehensive diagnostic and treatment facilities is reinforcing the segment’s leading market position globally.

The clinic segment is expected to witness the fastest CAGR of 6.8% from 2026 to 2033, driven by growing availability of outpatient breast care services, increasing accessibility to women’s healthcare clinics, and rising demand for cost-effective treatment solutions. Expanding preventive healthcare awareness and increasing adoption of minimally invasive diagnostic procedures are further supporting segment growth. Clinics are increasingly offering personalized consultation services, early-stage diagnostic evaluations, and hormonal therapy management for women with recurring breast symptoms. In addition, shorter waiting times, lower treatment costs, and improved accessibility compared to large hospital settings are encouraging higher patient preference for clinic-based care. Rising investments in specialty women’s healthcare centers and expanding private healthcare networks are also accelerating segment growth globally. Furthermore, increasing awareness regarding regular breast health monitoring and early intervention strategies is expected to strengthen long-term demand for clinic-based fibrocystic breast disease treatment services.

By Distribution Channel

On the basis of distribution channel, the global Fibrocystic Breast Disease Treatment market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market with a share of 46.15% in 2025 due to high prescription volumes associated with hospital-based diagnosis and treatment procedures. Hospital pharmacies provide direct access to specialist-prescribed medications, hormonal therapies, injectable treatments, and post-procedural care medicines, supporting strong segment demand. In addition, increasing hospitalization rates for breast diagnostics and surgical interventions are reinforcing segment dominance globally.

The online pharmacy segment is expected to witness the fastest CAGR of 7.0% from 2026 to 2033, driven by rising adoption of digital healthcare platforms, growing patient preference for home delivery services, and increasing accessibility to prescription medications through e-commerce channels. Expanding internet penetration, telemedicine integration, and improving digital pharmacy regulations across emerging economies are further accelerating the growth of the online pharmacy segment globally. Increasing utilization of mobile healthcare applications and digital prescription services is making medication access more convenient for patients managing chronic breast-related conditions. In addition, rising consumer preference for contactless purchasing options, discounted pricing models, and subscription-based medicine delivery services is supporting segment expansion. Healthcare providers and pharmacy chains are increasingly partnering with digital health platforms to improve medication availability and patient adherence. Furthermore, growing awareness regarding women’s healthcare products and expanding online pharmaceutical distribution networks are expected to strengthen long-term growth opportunities for the online pharmacy segment globally.

Global Fibrocystic Breast Disease Treatment Market Regional Analysis

North America dominated the Fibrocystic Breast Disease Treatment market and accounted for the largest revenue share of 36.18% in 2025, supported by advanced women’s healthcare infrastructure, rising awareness regarding early breast disease diagnosis, and increasing adoption of hormonal and minimally invasive treatment approaches. The region also benefits from strong availability of breast imaging technologies, favorable reimbursement policies, and increasing clinical focus on preventive breast healthcare. Growing demand for early diagnostic screening, increasing prevalence of hormonal breast disorders, and rising adoption of personalized treatment strategies continue to strengthen North America’s leadership position in the global market.

U.S. Fibrocystic Breast Disease Treatment Market Insight

The U.S. Fibrocystic Breast Disease Treatment market is witnessing strong growth due to increasing awareness regarding breast health, rising prevalence of benign breast disorders, and growing adoption of minimally invasive diagnostic and treatment procedures. The country’s advanced healthcare ecosystem, along with widespread access to mammography, ultrasound imaging, hormonal therapies, and specialty women’s healthcare services, is driving market demand. In addition, rising investments in breast cancer screening infrastructure and increasing emphasis on early diagnosis and preventive care are accelerating treatment adoption across hospitals and specialty clinics.

Europe Fibrocystic Breast Disease Treatment Market Insight

The Europe Fibrocystic Breast Disease Treatment market remains a major contributor to global revenue, driven by strong healthcare infrastructure, rising awareness regarding women’s preventive healthcare, and increasing adoption of advanced breast imaging technologies. The widespread use of mammography screening programs, hormonal therapies, and minimally invasive diagnostic procedures is supporting market expansion across the region. Increasing investments in women’s health research, coupled with favorable government healthcare initiatives and growing availability of specialty breast care centers, continue to enhance the adoption of Fibrocystic Breast Disease Treatment throughout Europe.

U.K. Fibrocystic Breast Disease Treatment Market Insight

The U.K. Fibrocystic Breast Disease Treatment market is experiencing steady growth, supported by rising awareness regarding breast disorders, increasing participation in national breast screening programs, and growing adoption of advanced diagnostic technologies. Increasing demand for minimally invasive treatment procedures and hormonal therapies is contributing to market growth. Furthermore, strong healthcare support systems, rising investment in women’s healthcare infrastructure, and improved access to specialized breast clinics are positioning the U.K. as a key market within the Fibrocystic Breast Disease Treatment industry.

Germany Fibrocystic Breast Disease Treatment Market Insight

The Germany Fibrocystic Breast Disease Treatment market is expanding steadily due to the country’s advanced diagnostic infrastructure, strong clinical research capabilities, and increasing adoption of modern breast imaging technologies. Hospitals and specialty healthcare providers are increasingly utilizing mammography, ultrasound, and biopsy procedures for accurate diagnosis and long-term patient management. Continuous advancements in minimally invasive treatment procedures, hormonal therapy approaches, and personalized women’s healthcare solutions, along with strong government support for preventive healthcare programs, are further driving market growth in Germany.

Asia-Pacific Fibrocystic Breast Disease Treatment Market Insight

The Asia-Pacific Fibrocystic Breast Disease Treatment market is expected to witness rapid growth, driven by improving healthcare accessibility, rising awareness regarding breast health, and expanding diagnostic capabilities across countries such as China, India, and Japan. Growing awareness regarding early disease detection, increasing adoption of breast imaging technologies, and rising demand for affordable treatment solutions are supporting regional market expansion. In addition, increasing government initiatives focused on women’s healthcare and expanding healthcare infrastructure are accelerating treatment adoption across hospitals and diagnostic centers throughout the region.

Japan Fibrocystic Breast Disease Treatment Market Insight

The Japan Fibrocystic Breast Disease Treatment market is witnessing consistent growth due to rising awareness regarding early breast disease diagnosis, increasing adoption of advanced imaging technologies, and strong focus on preventive women’s healthcare. Hospitals and specialty clinics are increasingly utilizing ultrasound, mammography, and minimally invasive procedures for accurate diagnosis and disease management. Moreover, growing demand for personalized hormonal therapies and the country’s focus on improving women’s healthcare outcomes are further contributing to market growth.

China Fibrocystic Breast Disease Treatment Market Insight

The China Fibrocystic Breast Disease Treatment market is growing rapidly, driven by improving healthcare infrastructure, increasing awareness regarding breast disorders, and rising government focus on women’s preventive healthcare programs. Growing adoption of advanced diagnostic technologies such as breast ultrasound and mammography across hospitals and diagnostic centers is significantly boosting market demand. In addition, rising healthcare expenditure, expanding access to specialty women’s healthcare services, and increasing awareness regarding early diagnosis and treatment are positioning China as one of the fastest-growing markets for Fibrocystic Breast Disease Treatment globally.

Global Fibrocystic Breast Disease Treatment Market Share

The Fibrocystic Breast Disease Treatment industry is primarily led by well-established companies, including:

• AbbVie Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Johnson & Johnson Services, Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Amgen Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• GlaxoSmithKline plc (U.K.)
• Sanofi S.A. (France)
• AstraZeneca plc (U.K.)
• Bayer AG (Germany)
• Merck & Co., Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Biocon Limited (India)
• Cipla Limited (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Lupin Limited (India)
• Zydus Lifesciences Ltd. (India)
• Dr. Reddy’s Laboratories Ltd. (India)
• Aurobindo Pharma Limited (India)
• Torrent Pharmaceuticals Ltd. (India)
• Viatris Inc. (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Organon & Co. (U.S.)
• Abbott Laboratories (U.S.)
• Siemens Healthineers AG (Germany)
• GE HealthCare Technologies Inc. (U.S.)
• Hologic, Inc. (U.S.)
• FUJIFILM Holdings Corporation (Japan)

Latest Developments in Global Fibrocystic Breast Disease Treatment Market

• In January 2022, researchers from Penn State Health published a radiologic-pathologic correlation study on fibrocystic breast changes using MRI imaging in the Journal of Breast Imaging. The study highlighted the growing role of breast MRI in differentiating benign fibrocystic changes from malignant lesions, improving diagnostic accuracy and supporting more precise patient management strategies in breast healthcare
• In August 2023, StatPearls Publishing updated its clinical review on Fibrocystic Breast Disease, highlighting growing adoption of hormonal therapies, minimally invasive cyst aspiration procedures, and advanced imaging technologies such as ultrasound and mammography for diagnosis and disease management. The publication emphasized increasing clinical focus on personalized treatment approaches and early detection strategies for benign breast disorders globally
• In April 2024, the U.S. Food and Drug Administration (FDA) approved Lumicell’s LUMISIGHT (pegulicianine) imaging agent for use during breast-conserving surgery. The technology helps surgeons detect residual cancerous tissue in real time during lumpectomy procedures through fluorescence-guided imaging. This development supports advancements in breast disease diagnosis and minimally invasive treatment approaches, improving surgical precision and reducing repeat surgery rates in breast care management
• In May 2025, the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines to recommend the use of FES PET imaging for systemic staging in patients with recurrent or metastatic invasive lobular breast cancer. GE HealthCare’s Cerianna (fluoroestradiol F18) imaging agent was highlighted for improving detection of estrogen receptor-positive breast lesions, supporting more accurate diagnosis and personalized treatment planning in breast disease management
• In October 2025, the American Society of Breast Surgeons (ASBrS) and the Society of Breast Imaging (SBI) released updated evidence-based guidelines for the management of benign breast lesions and fibroepithelial conditions. The guidelines focused on improving diagnostic pathways, reducing unnecessary surgical interventions, and enhancing personalized treatment strategies for benign breast disorders, including fibrocystic breast conditions

SKU-67569